GetTopicDetailResponse(id=9e4d12442935, topicName=Valaciclovir, introduction=, content=帶狀皰疹 Valaciclovir, image=null, comments=0, allHits=335, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu Feb 20 11:19:15 CST 2025, time=2025-02-20, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=501730, tagList=[TagDto(tagId=501730, tagName=Valaciclovir)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2252780, encodeId=95e12252e80ad, content=<a href='/topic/show?id=dde64855037' target=_blank style='color:#2F92EE;'>#帶狀皰疹#</a> <a href='/topic/show?id=9e4d12442935' target=_blank style='color:#2F92EE;'>#Valaciclovir#</a>, objectTitle=RMD Open:Valaciclovir有效降低系統(tǒng)性紅斑狼瘡患者使用Anifrolumab期間的帶狀皰疹風險, objectType=article, longId=863981, objectId=0ba986398134, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240624/1719199376884_92910.jpg, objectUrl=/article/show_article.do?id=0ba986398134, replyNumber=0, likeNumber=30, createdTime=2025-02-20, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=0ba986398134, moduleTitle=RMD Open:Valaciclovir有效降低系統(tǒng)性紅斑狼瘡患者使用Anifrolumab期間的帶狀皰疹風險, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0ba986398134)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-02-20發(fā)表于陜西省